Specific Sciences Corporation (NASDAQ: EXAS) reported better-than-expected third-quarter monetary outcomes and raised its FY25 sales assistance above price quotes on Monday.
Specific Sciences reported quarterly incomes of 24 cents per share which beat the expert agreement price quote of a loss of 7 cents per share. The business reported quarterly sales of $850.739 million which beat the expert agreement price quote of $810.178 million.
Specific Sciences raised its FY2025 sales assistance from $3.130 billion-$ 3.170 billion to $3.220 billion-$ 3.235 billion.
” Specific Sciences continues to advance our objective to avoid cancer and spot it previously through a ruthless concentrate on clients,” stated Kevin Conroy, chairman and CEO. “Our 3rd quarter results show the power of our patient-centric platform and our relied on brand names, Cologuard ® and Oncotype DX ®. The momentum we are constructing is sustaining development, advancing ingenious brand-new tests like Cancerguard, and enhancing our monetary efficiency.”
Specific Sciences shares acquired 3.5% to close at $66.98 on Monday.
These experts made modifications to their rate targets on Specific Sciences following incomes statement.
- BTIG expert Mark Massaro kept Specific Sciences with a Buy and raised the rate target from $75 to $85.
- Stifel expert Daniel Arias kept Specific Sciences with a Buy and raised the rate target from $67 to $80.
- Barclays expert Luke Sergott kept the stock with an Obese score and improved the rate target from $65 to $77.
Thinking about purchasing EXAS stock? Here’s what experts believe:
Read This Next:
Image by means of Shutterstock
Market News and Data gave you by Benzinga APIs